共 50 条
First-trimester Aneuploidy Screening Is There a Maternal Age at Which It Loses Effectiveness?
被引:0
|作者:
Lau, Gregory W.
[1
]
Feldman, Daniele S.
[1
]
Morales, Carlos M.
[1
]
Smith, Deebra
[1
]
Edwards, Rennatha
[1
]
Williams, John, III
[1
]
机构:
[1] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Los Angeles, CA 90048 USA
关键词:
advanced maternal age;
aneuploidy;
chromosomal abnormality;
first trimester screening;
nuchal translucency;
prenatal diagnosis;
Trisomy;
13;
18;
21;
DOWN-SYNDROME;
AMNIOCENTESIS;
RISK;
D O I:
暂无
中图分类号:
R71 [妇产科学];
学科分类号:
100211 ;
摘要:
OBJECTIVE: To determine the maternal age at which the likelihood of a screen-positive result justifies diagnostic testing. STUDY DESIGN: A retrospective review of women who presented for first-trimester screening using nuchal translucency (NT) measurements with or without serum biochemistry between January 2000December 2011. Using cutoffs of 1:300, 1:270, and 1:200, the Trisomy 21 (T21) screen-positive rates were stratified by maternal age. RESULTS: A total of 6,927 women underwent first-trimester screening; women with multiple gestations and/or using donor oocytes were excluded. Of the remaining women, 4,882 had combined NT and biochemistry results, while 1,767 had NT without serum screening results. Screen-positive rates were stratified by maternal age. An increase in the screen-positive rate is noted for both groups after age 40 but is more pronounced after age 43, where the screen-positive rate is 97.8% and 63.0% using cutoffs of 1:300 for the NT and NT and Biochemistry groups, respectively. CONCLUSION: Women undergoing first-trimester screening at age 40 have approximately 30% likelihood of screening positive for T21. This rate increases to roughly 7090% at age 44. This information will affect the counseling of patients who are considering prenatal screening versus diagnosis.
引用
收藏
页码:443 / 447
页数:5
相关论文